These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21986994)

  • 1. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.
    Besson D; Pavageau AH; Valo I; Bourreau A; Bélanger A; Eymerit-Morin C; Moulière A; Chassevent A; Boisdron-Celle M; Morel A; Solassol J; Campone M; Gamelin E; Barré B; Coqueret O; Guette C
    Mol Cell Proteomics; 2011 Dec; 10(12):M111.009712. PubMed ID: 21986994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of stromal proteins in different stages of colorectal cancer establishes Tenascin-C as a stromal biomarker for colorectal cancer metastasis.
    Li M; Peng F; Li G; Fu Y; Huang Y; Chen Z; Chen Y
    Oncotarget; 2016 Jun; 7(24):37226-37237. PubMed ID: 27191989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorbitol dehydrogenase overexpression and other aspects of dysregulated protein expression in human precancerous colorectal neoplasms: a quantitative proteomics study.
    Uzozie A; Nanni P; Staiano T; Grossmann J; Barkow-Oesterreicher S; Shay JW; Tiwari A; Buffoli F; Laczko E; Marra G
    Mol Cell Proteomics; 2014 May; 13(5):1198-218. PubMed ID: 24567419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The roles of JK-1 (FAM134B) expressions in colorectal cancer.
    Kasem K; Gopalan V; Salajegheh A; Lu CT; Smith RA; Lam AK
    Exp Cell Res; 2014 Aug; 326(1):166-73. PubMed ID: 24973512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of prohibitin as a potential biomarker for colorectal carcinoma based on proteomics technology.
    Chen D; Chen F; Lu X; Yang X; Xu Z; Pan J; Huang Y; Lin H; Chi P
    Int J Oncol; 2010 Aug; 37(2):355-65. PubMed ID: 20596663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteome analysis of formalin-fixed paraffin-embedded colorectal adenomas reveals the heterogeneous nature of traditional serrated adenomas compared to other colorectal adenomas.
    Sohier P; Sanson R; Leduc M; Audebourg A; Broussard C; Salnot V; Just PA; Pasmant E; Mayeux P; Guillonneau F; Romagnolo B; Perret C; Terris B
    J Pathol; 2020 Mar; 250(3):251-261. PubMed ID: 31729028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.
    Valo I; Raro P; Boissard A; Maarouf A; Jézéquel P; Verriele V; Campone M; Coqueret O; Guette C
    Proteomics; 2019 Nov; 19(21-22):e1800446. PubMed ID: 31318138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancer.
    Kahlert C; Lerbs T; Pecqueux M; Herpel E; Hoffmeister M; Jansen L; Brenner H; Chang-Claude J; Bläker H; Kloor M; Roth W; Pilarsky C; Rahbari NN; Schölch S; Bork U; Reissfelder C; Weitz J; Aust D; Koch M
    Int J Cancer; 2015 Nov; 137(9):2104-13. PubMed ID: 25951369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinicopathological significance of REIC expression in colorectal carcinomas.
    Wang W; Zhu W; Xu XY; Nie XC; Yang X; Xing YN; Yu M; Liu YP; Takano Y; Zheng HC
    Histol Histopathol; 2012 Jun; 27(6):735-43. PubMed ID: 22473694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer.
    Han CL; Chen JS; Chan EC; Wu CP; Yu KH; Chen KT; Tsou CC; Tsai CF; Chien CW; Kuo YB; Lin PY; Yu JS; Hsueh C; Chen MC; Chan CC; Chang YS; Chen YJ
    Mol Cell Proteomics; 2011 Apr; 10(4):M110.003087. PubMed ID: 21209152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic analysis reveals overexpression of moesin and cytokeratin 17 proteins in colorectal carcinoma.
    Kim CY; Jung WY; Lee HJ; Kim HK; Kim A; Shin BK
    Oncol Rep; 2012 Mar; 27(3):608-20. PubMed ID: 22076435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-depth proteomic delineation of the colorectal cancer exoproteome: Mechanistic insight and identification of potential biomarkers.
    Karagiannis GS; Pavlou MP; Saraon P; Musrap N; Xie A; Batruch I; Prassas I; Dimitromanolakis A; Petraki C; Diamandis EP
    J Proteomics; 2014 May; 103():121-36. PubMed ID: 24681409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPEP1, expressed in the early stages of colon carcinogenesis, affects cancer cell invasiveness.
    Toiyama Y; Inoue Y; Yasuda H; Saigusa S; Yokoe T; Okugawa Y; Tanaka K; Miki C; Kusunoki M
    J Gastroenterol; 2011 Feb; 46(2):153-63. PubMed ID: 20824289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissecting characteristics and dynamics of differentially expressed proteins during multistage carcinogenesis of human colorectal cancer.
    Peng F; Huang Y; Li MY; Li GQ; Huang HC; Guan R; Chen ZC; Liang SP; Chen YH
    World J Gastroenterol; 2016 May; 22(18):4515-28. PubMed ID: 27182161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinicopathologic significance of TUFM and p53 for the normal-adenoma-carcinoma sequence in colorectal epithelia.
    Xi HQ; Zhang KC; Li JY; Cui JX; Zhao P; Chen L
    World J Surg Oncol; 2017 Apr; 15(1):90. PubMed ID: 28449687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impacts of mammalian target of rapamycin expression in human colorectal cancers.
    Alqurashi N; Gopalan V; Smith RA; Lam AK
    Hum Pathol; 2013 Oct; 44(10):2089-96. PubMed ID: 23773481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterising the prognostic potential of HLA-DR during colorectal cancer development.
    Dunne MR; Phelan JJ; Michielsen AJ; Maguire AA; Dunne C; Martin P; Noonan S; Tosetto M; Geraghty R; Fennelly D; Sheahan K; Ryan EJ; O'Sullivan J
    Cancer Immunol Immunother; 2020 Aug; 69(8):1577-1588. PubMed ID: 32306077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted Proteomics for Multiplexed Verification of Markers of Colorectal Tumorigenesis.
    Uzozie AC; Selevsek N; Wahlander A; Nanni P; Grossmann J; Weber A; Buffoli F; Marra G
    Mol Cell Proteomics; 2017 Mar; 16(3):407-427. PubMed ID: 28062797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target proteomic profiling of frozen pancreatic CD24+ adenocarcinoma tissues by immuno-laser capture microdissection and nano-LC-MS/MS.
    Zhu J; Nie S; Wu J; Lubman DM
    J Proteome Res; 2013 Jun; 12(6):2791-804. PubMed ID: 23679566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.